For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Intarcia Therapeutics, Inc.

USPTO Granted Patents = 67

CIPO Patents = 8

EPO Patents = 12

Trademarks = 5

Forward Citations = 1,481

Loading Chart...

Loading Chart...

58 inventors (with patents filed for the assignee):

Catherine Manya Rohloff (24 out of 25 patents)

Pauline C Zamora (19 out of 19 patents)

Thomas R Alessi (18 out of 20 patents)

4. Scott D Lautenbach (15 out of 28 patents)

5. Michael A DesJardin (13 out of 19 patents)

6. Stan Lam (12 out of 12 patents)

7. Ryan D Mercer (9 out of 9 patents)

8. Bing Yang (9 out of 16 patents)

9. Stephen A Berry (8 out of 12 patents)

10. Guohua Chen (7 out of 42 patents)

11. Pedro E De La Serna (7 out of 11 patents)

12. Andrew S Luk (7 out of 14 patents)

13. Jay S Smith (7 out of 7 patents)

14. Michael R Cole (7 out of 28 patents)

15. Paul R Houston (7 out of 13 patents)

Core Competencies:

Peptide Tyrosine Tyrosine

Exenatide Administration

Osmotic Delivery Systems

Glucagon-Receptor Polypeptides

Implant Placement Guide

Suspension Formulations

Diabetes Treatment Methods

Viscous Liquid Formulations

Active Agent Delivery

Particle Formulations

Drug Delivery Devices

Flow Modulator Systems

67 patents: Sort by Forward Citations

1. 11739134 - Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use (2023-08-29),

2. 11654183 - Methods comprising continuous administration of exenatide and co-administration of a drug (2023-05-23),

3. D962433 - Implant placement guide (2022-08-30),

4. 11246913 - Suspension formulation comprising an insulinotropic peptide (2022-02-15),

5. 11214607 - Glucagon-receptor selective polypeptides and methods of use thereof (2022-01-04),

6. D933219 - Implant removal tool and assembly (2021-10-12),

7. D912249 - Implant removal tool (2021-03-02),

8. 10925639 - Implant placement and removal systems (2021-02-23),

9. 10869830 - Rapid establishment and/or termination of substantial steady-state drug delivery (2020-12-22),

10. 10835580 - Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug (2020-11-17),

11. 10583080 - Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c (2020-03-10),

12. 10527170 - Osmotic delivery systems and piston assemblies for use therein (2020-01-07),

13. 10501517 - Glucagon-receptor selective polypeptides and methods of use thereof (2019-12-10),

14. 10441528 - Devices, formulations, and methods for delivery of multiple beneficial agents (2019-10-15),

15. D860451 - Implant removal tool (2019-09-17),

Intarcia Therapeutics, Inc. is a biopharmaceutical company pioneering a novel approach to treat chronic diseases. They are focused on developing innovative therapies that improve outcomes and enhance the quality of life for patients. Intarcia's proprietary ITCA 650, an investigational therapy for the treatment of type 2 diabetes, represents their commitment to revolutionizing the landscape of chronic disease management. By delivering medicines directly into the subcutaneous tissue using their proprietary Medici Drug Delivery System™, Intarcia aims to provide long-term, continuous therapy for patients in a convenient and reliable manner.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

67 Patents

#38 in Boston, MA

#294 in Massachusetts

#5,271 in US

#10,742 in the World

Boston, MA, United States of America

Intarcia Therapeutics, Inc.

Forward Citations = 1,481

58 inventors:

Catherine Manya Rohloff (24 out of 25 patents)

Pauline C Zamora (19 out of 19 patents)

Thomas R Alessi (18 out of 20 patents)

4. Scott D Lautenbach (15 out of 28 patents)

5. Michael A DesJardin (13 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…